Marqibo, Oncovin (vincristine sulfate) is a small molecule pharmaceutical. Vincristine sulfate was first approved as Marqibo on 1982-01-01. It is used to treat hodgkin disease, leukemia, neuroblastoma, non-hodgkin lymphoma, and rhabdomyosarcoma amongst others in the USA. The pharmaceutical is active against tubulin beta chain.
|Trade Name||Marqibo, Oncovin|
|Common Name||Vincristine sulfate|
|Indication||hodgkin disease, leukemia, neuroblastoma, non-hodgkin lymphoma, rhabdomyosarcoma, wilms tumor|
|Drug Class||Vinca alkaloids|